Adocia S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADOCY research report →
About the company
Adocia S. A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides.
- CEO
- Olivier Soula
- IPO
- 2014
- Employees
- 78
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $170.44M
- P/E
- -5.26
- P/S
- 59.71
- P/B
- 58.57
- EV/EBITDA
- -5.19
- Div Yield
- 0.00%
- Gross Margin
- -1213.97%
- Op Margin
- -1229.56%
- Net Margin
- -1124.81%
- ROE
- -3796.57%
- ROIC
- -142.92%
- Revenue
- $1.42M · -84.80%
- Net Income
- $-15,936,197 · -70.97%
- EPS
- $-0.81 · -22.73%
- Op Income
- $-17,421,181
- FCF YoY
- 58.79%
- 52W High
- $11.80
- 52W Low
- $11.80
- 50D MA
- $11.80
- 200D MA
- $11.80
- Beta
- 0.86
- Avg Volume
- 112
Get TickerSpark's AI analysis on ADOCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ADOCY coverage
Recent articles, reports, and earnings notes.
No research on ADOCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADOCY report →Similar companies
Peers in the same neighborhood.